Medtronic CoreValve/Evolut ™ Demonstrates Best Durability

Medtronic today announced five-year bioprosthetic valve dysfunction (BVD) data for the CoreValve/Evolut ™ platform, the first and only transcatheter aortic valve replacement (TAVR) platform to show significantly better valve performance and durability compared to surgical aortic valve replacement (SAVR) at five years. Data, presented by Dr. Steven Yakubov, in a late-breaking clinical trial session a t the 2023 annual meeting of Cardiovascular Research Technologies (CRT 2023), build upon the excellent results of the structural valve deterioration (SVD) analysis recently published in JAMA Cardiology.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news